title: Efficacy of antihypertensive therapy in decreasing renal and cardiovascular complications in diabetes mellitus.
abstract: The mechanism underlying the pathogenesis of microangiopathy and macroangiopathy in diabetes mellitus is hypothesized to be chronic hyperglycaemia. However, the values of blood glucose at which chronic diabetic complications develop at the renal and cardiac level are quite different. It is not clear whether this is due to different responses of kidney and heart tissues to the metabolic challenge of diabetes, or to the simultaneous role of other mechanisms contributing differently to the pathogenesis of chronic diabetic complications in renal and cardiac tissues. One of these mechanisms could be the simultaneous occurrence of arterial hypertension along with hyperglycaemia in diabetic patients. We reviewed the available evidence in the recent medical literature and provide information on the relationships between hyperglycaemia and cardiovascular and renal complications in insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM). The majority of reports indicate that the values of blood glucose appearing to be at threshold level for the development of cardiovascular complications are significantly lower than those determining renal complications (5.4 vs 10.0 mmol/l blood glucose concentrations 2 h after an oral glucose tolerance test). This was the case both in cross-sectional and prospective studies and also in intervention studies aimed at decreasing blood glucose concentrations by using strict metabolic control methods (The Diabetes Control and Complications Trial Research Group), which succeeded in delaying the rate of occurrence of microangiopathic complications at the kidney and retinal level but not so effectively at the cardiac level. Therefore, alternative therapeutic or supplementary strategies to blood glucose control should be adopted in diabetes to prevent diabetic complications. To date, the most effective approach, from our point of view, is antihypertensive therapy in order to prevent end-stage renal disease. We extensively reviewed the available literature which reported comparisons between angiotensin-converting enzyme inhibitors (ACE inhibitors) and calcium channel blockers (CCBs) in the treatment of arterial hypertension in diabetes. Intensified antihypertensive therapy achieving a blood pressure level below 130/85 mmHg has been shown to be useful in decreasing the rate of occurrence of chronic diabetic complications in diabetes mellitus. Both ACE inhibitors and CCBs have been shown to significantly improve the course of renal function in diabetic patients with incipient and overt nephropathy.
authors.affiliation: Department of Clinical Medicine, University of Sassari, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Nosadini
authors.forename: C
authors.initials: C
authors.lastname: Abaterusso
authors.forename: M
authors.initials: M
authors.lastname: Dalla Vestra
authors.forename: E
authors.initials: E
authors.lastname: Bortoloso
authors.forename: A
authors.initials: A
authors.lastname: Saller
authors.forename: M
authors.initials: M
authors.lastname: Bruseghin
authors.forename: A
authors.initials: A
authors.lastname: Sfriso
authors.forename: M
authors.initials: M
authors.lastname: Trevisan
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000188:drug therapy*; D003925:Diabetic Angiopathies / Q000188:drug therapy* / Q000517:prevention & control*; D003928:Diabetic Nephropathies / Q000517:prevention & control*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers